Old drug, new tricks: the utility of metformin in infection and vaccination responses to influenza and SARS-CoV-2 in older adults.
Old drug, new tricks: the utility of metformin in infection and vaccination responses to influenza and SARS-CoV-2 in older adults.
复制标题
DOI：
10.3389/fragi.2023.1272336
复制
发表时间：
2023
影响因子：
--
通讯作者：
Bartley, Jenna M.
中科院分区：
文献类型：
--
作者：
Martin, Dominique E.;Cadar, Andreia N.;Bartley, Jenna M.
面对流感和严重急性呼吸道综合征冠状病毒2型（SARS-CoV-2）等全球病原体，老年人由于年龄相关的免疫失调，更容易患上严重疾病并死于这些感染，因此迫切需要标准疫苗和病毒特异性治疗之外的策略。因此，需要补充治疗来解决老年人并发症和死亡风险增加的问题。FDA批准的糖尿病药物二甲双胍是一种有吸引力的治疗候选药物，可改善面临病毒挑战的老年人的免疫防御和恢复力。二甲双胍已经是一种候选的抗衰老药物，但它的益处有可能超越这一点，并改善特异性免疫反应。Metalloprotein可以靶向多种衰老标志，并直接影响先天和适应性免疫细胞亚群。回顾性和前瞻性研究都证明了二甲双胍在改善SARS-CoV-2或流感感染后的结局方面的疗效。此外，来自临床试验的证据也表明二甲双胍治疗可以改善疫苗接种反应。总的来说，这些发现表明二甲双胍可以改善与年龄相关的免疫恢复力下降。改善感染后结果或改善疫苗诱导保护的策略对老年人来说是非常宝贵的。此外，重新利用已经FDA批准的药物的能力在必要的时间和资源方面具有显著的优势。因此，二甲双胍具有很大的潜力，可以作为一种治疗药物，改善流感和SARS-CoV-2感染期间与年龄相关的免疫失调，应该进一步探索，以确认其改善老年人整体免疫恢复能力的能力。
In the face of global pathogens such as influenza (flu) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), strategies beyond standard vaccines and virus-specific treatments are critically needed for older populations who are more susceptible to severe disease and death from these infections due to age-related immune dysregulation. Thus, complimentary therapeutics are needed to address the increased risk of complications and death in older adults. Metformin, an FDA approved diabetes drug, is an attractive therapeutic candidate to improve immune defenses and resilience in older adults facing viral challenge. Metformin is already a candidate anti-aging drug, but its benefits have potential to span beyond this and improve specific immune responses. Metformin can target multiple aging hallmarks as well as directly impact innate and adaptive immune cell subsets. Both retrospective and prospective studies have demonstrated metformin’s efficacy in improving outcomes after SARS-CoV-2 or flu infections. Moreover, evidence from clinical trials has also suggested that metformin treatment can improve vaccination responses. In totality, these findings suggest that metformin can improve age-related declines in immunological resilience. Strategies to improve outcomes after infection or improve vaccine-induced protection are invaluable for older adults. Moreover, the ability to repurpose an already FDA approved drug has significant advantages in terms of necessary time and resources. Thus, metformin has great potential as a therapeutic to improve age-related immune dysregulation during flu and SARS-CoV-2 infections and should be further explored to confirm its ability to improve overall immunological resilience in older adults.
登录
查看更多内容
N3C数据库中的糖尿病药物和与COVID-19结果的关联：国家回顾性队列研究。
影响因子：
3.7
作者：
Bramante, Carolyn T.;Johnson, Steven G.;Garcia, Victor;Evans, Michael D.;Harper, Jeremy;Wilkins, Kenneth J.;Huling, Jared D.;Mehta, Hemalkumar;Alexander, Caleb;Tronieri, Jena;Hong, Stephenie;Kahkoska, Anna;Alamgir, Joy;Koraishy, Farrukh;Hartman, Katrina;Yang, Kaifeng;Abrahamsen, Trine;Sturmer, Til;Buse, John B.
通讯作者：
Buse, John B.
影响因子：
12.4
作者：
Chen S;Gan D;Lin S;Zhong Y;Chen M;Zou X;Shao Z;Xiao G
通讯作者：
Xiao G
影响因子：
5.1
作者：
Campos Caldas Rosa, Erica Carine;Cruz dos Santos, Renan Renato;Amato, Angelica Amorim
通讯作者：
Amato, Angelica Amorim
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
DOI：
10.1056/nejmoa2201662
发表时间：
2022-08-18
期刊：
The New England journal of medicine
影响因子：
--
作者：
通讯作者：
--